Overview

A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms

Status:
Completed
Trial end date:
2009-10-01
Target enrollment:
0
Participant gender:
All
Summary
The purpose of this study is to assess if the presence of BAK in a fluoroquinolone in the study eye affects the development of resistant bacteria on the conjunctiva based upon changes in the surface flora over the course of 2 weeks of topical treatment in healthy adult subjects.
Phase:
Phase 4
Accepts Healthy Volunteers?
Accepts Healthy Volunteers
Details
Lead Sponsor:
Allergan
Treatments:
Benzalkonium Compounds
Fluoroquinolones
Gatifloxacin
Moxifloxacin
Norgestimate, ethinyl estradiol drug combination
Ophthalmic Solutions
Pharmaceutical Solutions
Criteria
Inclusion Criteria:

- Male or Female

- At least 50 years of age

- In good general health

Exclusion Criteria:

- Any ocular surgery or use of topical antibiotics or antiseptics in either eye within
the last 3 months

- Use of topical steroids, or non-steroidal anti inflammatory drugs in either eye within
30 days of Baseline (or anticipated during the study)

- Use of lid scrubs within 7 days of Baseline in either eye (or anticipated use during
the study)